Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Histone Demethylase
    (5)
  • Antibacterial
    (1)
  • Glucokinase
    (1)
  • Histone Methyltransferase
    (1)
  • Others
    (6)
Filter
Search Result
Results for "

kdm5b

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    14
    TargetMol | Inhibitors_Agonists
  • Isotope Products
    1
    TargetMol | Isotope_Products
KDM5B-IN-3
T615651385101-10-9
KDM5B-IN-3 (Compound 5) is an inhibitor of histone lysine-specific demethylase 5B (KDM5B) or JARID1B, with an IC50 value of 9.32 μM, and serves as a valuable tool in gastric cancer research [1].
  • $1,520
6-8 weeks
Size
QTY
qc6352
T167001851373-36-8In house
QC6352 is a selective and effective KDM4C inhibitor (IC50: 35 nM).
  • $1,520
3-6 months
Size
QTY
KDM4-IN-2
T117492369607-62-3In house
KDM4-IN-2 is a potent and selective KDM4 KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.
  • $1,520
8-10 weeks
Size
QTY
KDOAM-25 citrate
T117502448475-08-7
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor, with IC50 values of 71 nM, 19 nM, 69 nM, and 69 nM for KDM5A, KDM5B, KDM5C, and KDM5D, respectively. Multiple myeloma MM1S cells treated with KDOAM-25 citrate show increased global H3K4 methylation at transcriptional start sites and impaired proliferation [1].
  • $1,820
10-14 weeks
Size
QTY
KDOAM-25 trihydrochloride (2230731-99-2 free base)
KDOAM-25 trihydrochloride
T11750L
KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor
  • $1,820
10-14 weeks
Size
QTY
KDOAM-25
T117512230731-99-2
KDOAM-25, a potent and highly selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM for KDM5A, 19 nM for KDM5B, 69 nM for KDM5C, and 69 nM for KDM5D, enhances global H3K4 methylation at transcriptional start sites and reduces proliferation in multiple myeloma MM1S cells.
  • $1,619
6-8 weeks
Size
QTY
KDM5A-IN-1
T156501905481-36-8
KDM5A-IN-1 is an orally available, potent and selective inhibitor of the pan-histidine lysine demethylase 5 KDM5, inhibiting KDM5A, KDM5B, and KDM5C with IC50 values of 45 nM, 56 nM, and 55 nM, respectively.KDM5A-IN-1 inhibits PC9 H3K4Me3, and may be useful in cancer research.
  • $149
In Stock
Size
QTY
PBIT
T164352514-30-9
PBIT inhibits JARID1B histone demethylase (IC50 of about 3 μM). PBIT also inhibits JARID1A and JARID1C (IC50s of 6 μM and 4.9 μM, respectively). PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes .
  • $34
In Stock
Size
QTY
YUKA1
YUKA 1
T17278708991-09-7
YUKA1, a cell-permeable KDM5A inhibitor (IC50=2.66 μM) with a weak effect on KDM5C (IC50=7.12 μM) and no effect on other KDM isoforms, was able to increase the level of H3K4me3 in human cells and inhibit the proliferation of cancer cells, and also prevented the emergence of drug-resistant cells.
  • $113
In Stock
Size
QTY
KDM5-C49 HCl
KDOAM-20 hydrochloride, KDM5-C49 HCl(1596348-16-1 Free base)
T27723L
KDM5-C49 HCl (KDOAM-20 hydrochloride) is a potent and selective inhibitor of KDM5 demethylase. KDM5-C49 HCL(1596348-16-1 Free base) is a candidate compound for the treatment of cancer.
  • $195
In Stock
Size
QTY
tk-129
T60713
TK-129 is an orally active, potent inhibitor of KDM5B with an IC50 of 44 nM and is low-toxicity. TK-129 exhibits cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 can be used in cardiovascular disease studies to reduce isoprenaline-induced myocardial remodelling and fibrosis in vivo, as well as to reduce ang II-induced activation of cardiac fibroblasts in vitro [1].
  • $789
10-14 weeks
Size
QTY
KDOAM-25 trihydrochloride
T62166
KDOAM-25 trihydrochloride is a potent and highly selective inhibitor of histone lysine demethylase 5 (KDM5), targeting KDM5A (IC50: 71 nM), KDM5B (IC50: 19 nM), KDM5C (IC50: 69 nM), and KDM5D (IC50: 69 nM). It enhances overall H3K4 methylation at the transcription start site and hinders the proliferation of multiple myeloma [MM1S cells].
  • $1,520
10-14 weeks
Size
QTY
Roxadustat-d5
T699662043026-13-5
Roxadustat-d5 is intended for use as an internal standard for the quantification of roxadustat by GC- or LC-MS. Roxadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH; IC50s = 1.4, 1.26, and 1.32 µM for HIF-PH1, HIF-PH2, and HIF-PH3, respectively). It is selective for HIF-PH over other 2-oxoglutarate-dependent dioxygenases, including lysine-specific demethylase 5A (KDM5A), KDM5B, -5C, -5D, and -6B (IC50s = >100 µM for all). Roxadustat (10-200 µM) stabilizes HIF-1α and HIF-2α in Hep3B hepatocellular carcinoma cells. It increases levels of secreted erythropoietin in Hep3B cells in a concentration-dependent manner and increases erythropoiesis in rats when administered at doses of 25 and 50 mg kg. Roxadustat reverses anemia in a rat model of chronic inflammation induced by peptidoglycan-polysaccharide, as well as a rat model of chronic kidney disease induced by 5 6 nephrectomy. It reduces tumor growth and increases survival in a murine Lewis lung carcin......
  • TBD
35 days
Size
QTY
KDM5-C49 hydrochloride
T73849
KDM5-C49 (KDOAM-20) hydrochloride is a potent, selective inhibitor of the KDM5 family of demethylases, with IC50 values of 40 nM for KDM5A, 160 nM for KDM5B, and 100 nM for KDM5C. This compound is utilized in cancer research [1].
  • $122
5 days
Size
QTY